'use strict';

/**
 * @ngdoc function
 * @name oncokbStaticApp.controller:MainCtrl
 * @description
 * # MainCtrl
 * Controller of the oncokbStaticApp
 */
angular.module('oncokbStaticApp')
    .controller('NewsCtrl', function($scope, $rootScope) {
        $scope.data = {
            citationURL: $rootScope.data.citationURL
        };
        $scope.data.updatedActionableGenes = {
            '03072017': {
                '1': [
                    'Updated alterations for EGFR - Non-Small Cell Lung Cancer - EGFR TKIs',
                    'Updated alterations for KIT - Gastrointestinal Stromal Tumor - Imatinib, Sunitinib, Regorafenib'
                ],
                '2': [
                    'CDK4 - Amplification - Well-Differentiated Liposarcoma/Dedifferentiated Liposarcoma - Palbociclib, Abemaciclib (<b>disease changed from Soft Tissue Sarcoma and Abemaciclib added</b>)',
                    'TSC1 - Renal Cell Carcinoma - Everolimus (<b>new association</b>)'
                ],
                '3': [
                    'ESR1 - Oncogenic Mutations - AZD9496, Fulvestrant (<b>new association</b>)',
                    'FGFR1 - Amplification - Breast Cancer - Dovitinib (<b>removed</b>)',
                    'FGFR1 - Amplification - Lung Squamous Cell Carcinoma - Debio1347 (<b>new association</b>)',
                    'FGFR2 - Amplification - Breast Cancer - Dovitinib (<b>removed</b>)',
                    'FGFR2/3 - Fusions - Various tumor types - Debio1347 (<b>new association</b>)',
                    'FGFR3 - Hotspots - Bladder Cancer - Debio1347, JNJ-42756493 (<b>new association</b>)',
                    'KRAS - Oncogenic Mutations - Colorectal Cancer - Atezolizumab+Cobimetinib (<b>moved from 4 to 3A only in CRC</b>)',
                    'MDM2 - Amplification - Liposarcoma - DS-3032b and RG7112 (<b>new association</b>)',
                    'PIK3CA - Oncogenic Mutations - Breast Cancer - Alpelisib+Fulvestrant, Buparlisib+Fulvestrant, Copanlisib, GDC0077, Serabelisib, Fulvestrant+Taselisib (<b>new drugs added</b>)'
                ],
                '4': [
                    'EGFR alterations - Glioma - Erlotinib (<b>removed</b>)',
                    'MDM2 - Amplification - Liposarcoma - DS-3032b (<b>moved to 3A</b>)',
                    'PIK3CA - Oncogenic Mutations - Breast Cancer - Alpelisib+Fulvestrant (<b>moved to 3A</b>)',
                    'IDH1 - R132 alterations - Chondrosarcoma - AG-120 (<b>moved from 3A to 4</b>)'
                ]
            },
            '04052017': {
                '1': [
                    'BRCA1/2 - Oncogenic Mutations - Ovarian Cancer - Niraparib FDA approval added',
                    'BRCA1/2 - Oncogenic Mutations - Ovarian Cancer - Rucaparib (<b>new publication added</b>)',
                    'Updated alterations for KIT - Gastrointestinal Stromal Tumor - Imatinib, Sunitinib, Regorafenib'
                ],
                '2': [
                    'Updated alterations for KIT - Gastrointestinal Stromal Tumor - Nilotinib, Dasatinib, Sorafenib',
                    'Updated alterations for KIT - Thymic cancer - Sunitinib, Sorafenib'
                ],
                '3': [
                    'BRAF V600 - Colorectal Cancer - Encorafenib + Binimetinib + Cetuximab (<b>new association</b>)',
                    'FGFR1 - Amplification - Lung Squamous Cell Carcinoma - AZD4547, Debio1347 (<b>new abstract added</b>)',
                    'FGFR2 - Fusions - Cholangiocarcinoma - BGJ398, Debio1347 (<b>new abstract added</b>)',
                    'Updated alterations for FGFR3 - Bladder cancer - JNJ-42756493, Debio1347',
                    'PIK3CA - Oncogenic mutations - Breast cancer - Updated treatments and evidence'
                ],
                '4': [
                    'BRAF V600 - Colorectal Cancer - Radiation + Trametinib + Fluorouracil (<b>new association</b>)',
                    'Updated alterations for FGFR3 - Breast cancer - Debio1347',
                    'KRAS - Wildtype - Updated treatments and evidence',
                    'KRAS - Oncogenic mtuations - Updated treatments and evidence',
                    'PIK3CA - Oncogenic mutations - Breast cancer - Updated treatments and evidence',
                    'PTEN - Oncogenic mutations - Breast cancer - Updated treatments and evidence'
                ]
            },
            '02022018': {
                '1': [
                    'November 6, 2017: <a target="_blank" ' +
                    'href="https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm583931.htm">' +
                    'the FDA approved vemurafenib</a> for treatment of patients with Erdheim-Chester disease (histiocytosis) who harbor BRAF V600 mutations.'
                ],
                '3': [
                    'HRAS - Oncogenic mutations - Head and Neck Squamous Cell Carcinoma - Tipifarnib (<b>moved from 4 to 3A only for HNSCC</b>)'
                ]
            },
            '07122018': {
                '1': [
                    'April 18, 2018: <a target="_blank" ' +
                    'href="https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm605113.htm">' +
                    'the FDA approved osimertinib</a> for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations.',
                    'May 4, 2018: <a target="_blank" ' +
                    'href="https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm606708.htm">' +
                    'the FDA approved the combination of dabrafenib plus trametinib</a> for treatment of patients with locally advanced or metastatic anaplastic thyroid cancer with BRAF V600E mutation and with no satisfactory locoregional treatment options.',
                    'June 27, 2018: <a target="_blank" ' +
                    'href="https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm611981.htm">' +
                    'the FDA approved the combination of encorafenib plus binimetinib</a> for patients with BRAF V600E- or V600K-mutant metastatic and/or unresectable melanoma.',

                ],
                '3': [
                    'EGFR - Exon 20 insertions - Non-small cell lung cancer - Poziotinib (<b>added as new association</b>)',
                    'ALK - G1202R - Non-small cell lung cancer - Lorlatinib (<b>added as new association</b>)',
                    'KIT - D816 mutations - Mastocytosis - Avapritinib (<b>added as new association</b>)',
                    'MTOR - E2014K, E2419K - Bladder cancer - Everolimus (<b>updated association</b>)',
                    'MTOR - L1460P, L2209V, L2427Q - Renal cell carcinoma - Temsirolimus (<b>updated association</b>)',
                    'MTOR - Q2223K - Renal cell carcinoma - Everolimus (<b>updated association</b>)'
                ]
            },
            '08172018': {
                '1': [
                    'July 20, 2018: <a target="_blank" ' +
                    'href="https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm614128.htm">' +
                    'the FDA approved ivosidenib</a> for adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test.',
                ]
            },
            '10012018': {
                '3': [
                    'RET - Oncogenic Mutations - Medullary Thyroid Cancer - LOXO-292 (<b>added as new association</b>)',
                ]
            },
            '10262018': {
                '4': [
                    'ALK - C1156Y, G1269A, I1171N, L1196M - Non-Small Cell Lung Cancer - Lorlatinib',
                    'EGFR - D761Y - Non-Small Cell Lung Cancer - Osimertinib'
                ]
            },
            '11022018': {
                '2': [
                    'RET - Fusions - Non-Small Cell Lung Cancer - LOXO-292 (<b>added as new association</b>)',
                ]
            },
            '12142018': {
                '1': [
                    'November 26, 2018: <a target="_blank" ' +
                    'href="https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm626720.htm">' +
                    'the FDA approved larotrectinib</a> for adult and pediatric patients with solid tumors that have an NTRK1, -2, or -3 gene fusion without a known acquired resistance mutation.'
                ],
                '2': [
                    'BRCA1/2 - Oncogenic Mutations - Breast Cancer - Talazoparib (<b>new association</b>)',
                    'RET - Fusions - Non-Small Cell Lung Cancer - BLU-667 (<b>new association</b>)'
                ],
                '3': [
                    'BRAF - V600E - Colorectal Cancer - Encorafenib + Binimetinib + Cetuximab (<b>new association</b>)',
                    'ERBB2 - Oncogenic Mutations - Non-Small Cell Lung Cancer - Ado-trastuzumab Emtansine (<b>new association</b>)',
                    'RET - Oncogenic Mutations - Medullary Thyroid Cancer - BLU-667 (<b>new association</b>)',
                ],
                '4': [
                    'KDM6A - Oncogenic Mutations - Bladder Cancer - EZH2 inhibitors (<b>new association</b>)',
                ]
            },
            '01242019': {
                '1': [
                    'November 2, 2018: <a target="_blank" ' +
                    'href="https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm625027.htm">' +
                    'the FDA approved lorlatinib</a> for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor or whose disease has progressed on alectinib or ceritinib for metastatic disease.'
                ]
            },
            '05092019': {
                '1': [
                    'April 12, 2019: <a target="_blank" ' +
                    'href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-erdafitinib-metastatic-urothelial-carcinoma">' +
                    'the FDA approved erdafitinib</a> for patients with locally advanced or metastatic urothelial carcinoma, with susceptible FGFR3 or FGFR2 genetic alterations (FGFR2 Fusions, FGFR3 Fusions or FGFR3 R248C, S249C, G370C, Y373C mutations), that has progressed during or following platinum-containing chemotherapy.'
                ],
                '4': [
                    'MET - Fusions - All Tumors - Crizotinib (<b>new association</b>)',
                    'CDK12 - Truncating Mutations - All Tumors - Pembrolizumab, Nivolumab, Cemiplimab (<b>new association</b>)',
                ],
            },
            '06212019': {
                '1': [
                    'PIK3CA - Oncogenic Mutations - Breast Cancer - Alpelisib (<b>previously level 3A</b>)<br/>' +
                    'May 24, 2019: <a target="_blank" ' +
                    'href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-alpelisib-metastatic-breast-cancer">The FDA approved PI(3)-kinase alpha selective inhibitor alpelisib</a> in combination with fulvestrant, to treat patients with HR+/ HER2- PIK3CA-mutant advanced or metastatic breast cancer.',
                ],
                '2': [
                    'BRAF - V600E - Colorectal Cancer - Encorafenib + Binimetinib + Cetuximab (<b>previously level 3A</b>)',
                    'ERBB2 - Amplification - Uterine Serous Carcinoma - Trastuzumab + Carboplatin-Paclitaxel (<b>previously level 2B</b>)',
                ],
            },
        };
        $scope.data.newlyAddedLevelFour = [
            {
                'gene': 'ATM',
                'mutation': 'Oncogenic Mutations',
                'tumorType': 'Prostate Cancer',
                'drug': 'Olaparib'
            },
            {
                'gene': 'BRAF',
                'mutation': 'D287H, D594A, D594G, D594H, D594N, F595L, G464E, G464V, G466A, G466E, G466V, G469A, G469E, G469R, G469V, G596D, G596R, K601N, K601T, L597Q, L597V, N581I, N581S, S467L, V459L',
                'tumorType': 'All Tumors',
                'drug': 'PLX8394'
            },
            {
                'gene': 'CDKN2A',
                'mutation': 'Oncogenic Mutations',
                'tumorType': 'All Tumors',
                'drug': 'Abemaciclib, Palbociclib, Ribociclib'
            },
            {
                'gene': 'EGFR',
                'mutation': 'A289V, R108K, T263P',
                'tumorType': 'Glioma',
                'drug': 'Lapatinib'
            },
            {
                'gene': 'EGFR',
                'mutation': 'Amplification',
                'tumorType': 'Glioma',
                'drug': 'Lapatinib'
            },
            {
                'gene': 'EWSR1',
                'mutation': 'EWSR1-FLI1 Fusion',
                'tumorType': 'Ewing Sarcoma',
                'drug': 'TK216'
            },
            {
                'gene': 'FGFR1',
                'mutation': 'Oncogenic Mutations',
                'tumorType': 'All Tumors',
                'drug': 'AZD4547, BGJ398, Debio1347, Erdafitinib'
            },
            {
                'gene': 'FGFR2',
                'mutation': 'Oncogenic Mutations',
                'tumorType': 'All Tumors',
                'drug': 'AZD4547, BGJ398, Debio1347, Erdafitinib'
            },
            {
                'gene': 'KRAS',
                'mutation': 'Oncogenic Mutations',
                'tumorType': 'All Tumors',
                'drug': 'KO-947, LY3214996, Ravoxertinib, Ulixertinib'
            },
            {
                'gene': 'MTOR',
                'mutation': 'Oncogenic Mutations',
                'tumorType': 'All Tumors',
                'drug': 'Everolimus, Temsirolimus'
            },
            {
                'gene': 'NF1',
                'mutation': 'Oncogenic Mutations',
                'tumorType': 'All Tumors',
                'drug': 'Cobimetinib, Trametinib'
            },
            {
                'gene': 'PTEN',
                'mutation': 'Oncogenic Mutations',
                'tumorType': 'All Tumors',
                'drug': 'AZD8186, GSK2636771'
            },
            {
                'gene': 'SMARCB1',
                'mutation': 'Oncogenic Mutations',
                'tumorType': 'All Tumors',
                'drug': 'Tazemetostat'
            }
        ];
        $scope.data.newlyAddedGenes = {
            '08172018': ['ACTG1', 'ARHGEF28', 'ARID3A', 'ARID3B', 'ARID3C', 'ARID4A', 'ARID4B', 'ARID5A', 'ATP6AP1', 'ATP6V1B2', 'ATXN2', 'BACH2', 'BCL11B', 'BCORL1', 'BCR', 'BTG1', 'CD28', 'CD58', 'CIITA', 'CRBN', 'CUX1', 'DDX3X', 'DTX1', 'DUSP22', 'EGR1', 'EP400', 'ESCO2', 'ETNK1', 'FANCD2', 'FAS', 'FBXO11', 'FURIN', 'GNA12', 'GNA13', 'GNB1', 'GTF2I', 'HDAC1', 'HDAC4', 'HDAC7', 'HIF1A', 'HIST1H1B', 'HIST1H1D'],
            '10012018': ['HIST1H1E', 'SETD6', 'SETD5', 'SETD7', 'SETDB2', 'SETDB1', 'SETD4', 'SETD3', 'SETD1B', 'U2AF2', 'TET3', 'NFE2', 'IRF8', 'IRF1', 'IKZF3', 'JARID2', 'NCSTN', 'HIST1H2BO', 'HIST1H2AC', 'HIST1H2BG', 'HIST1H2BJ', 'HIST1H2BK', 'HIST1H2BC', 'HIST1H2AG', 'HIST1H2AL', 'HIST1H2AM', 'TYK2'],
            '10262018': ['NT5C2', 'P2RY8', 'PCBP1', 'PDS5B', 'PTPN1', 'PTPN2 ', 'STAG1', 'TRAF3', 'TRAF5'],
            '12142018': ['KSR2', 'LCK', 'LTB', 'MGAM', 'MOB3B', 'MPEG1', 'NCOR2', 'PIGA', 'PLCG1', 'POT1', 'ROBO1', 'RUNX1T1', 'SAMHD1', 'SETD1A', 'SGK1', 'SMC1A', 'SMC3', 'SMG1', 'SP140', 'STAT6', 'TBL1XR1', 'UBR5', 'VAV1', 'VAV2', 'XBP1'],
            '01242019': ['ECT2L', 'RELN', 'TAL1', 'MLLT10', 'TLX3', 'TLX1', 'TRA', 'TRB', 'TRD', 'TRG', 'EPOR', 'ABL2', 'MECOM', 'DEK', 'RBM15', 'BCL9'],
            '05092019': ['ATF1', 'CCNB3', 'CMTR2', 'CREB1', 'CTR9', 'CXORF67', 'DDIT3', 'ETAA1', 'ETV5', 'FEV', 'FLI1', 'IL3', 'KAT6A', 'KBTBD4', 'KLF2', 'LMO2', 'LZTR1', 'MAF', 'MAFB', 'NR4A3', 'NRG1', 'NUP98', 'PDGFB', 'PGBD5', 'PHF6', 'PRKACA', 'SETBP1', 'SLFN11', 'SPRTN', 'SS18', 'TCL1A', 'TCL1B', 'TFE3', 'TRIP13', 'USP8', 'YY1', 'ZNRF3'],
            '08022019': ['ATXN7', 'MTAP', 'SERPINB3', 'SERPINB4'],
            '08282019': ['ARHGAP35', 'FOXF1', 'GAB1', 'MAD2L2', 'SMARCA2', 'SMARCE1'],
        };
    });
